Media.Player

Novel Molecular Aging Pathway to Predict, Delay, and Treat Neurological Diseases

Detailed Technology Description

None

*Abstract

BackgroundWhile most people develop ParkinsonΓÇÖs disease or AlzheimerΓÇÖs disease relatively later in life, other patients develop these diseases before age 50 (PD) or 65 (AD) and are categorized as having early onset disease. The mechanism(s) underlying age thresholds and the factors that contribute to individual variability in ages of onset within diseases are largely unknown. Understanding the factors that contribute to early disease development may help in diagnosis and treatment of affected individuals.Technology DescriptionInvestigators have identified genetic pathways related to mitochondrial dysfunction. This dysfunction may contribute to the early development of either PD or AD. Patients with the SIRT5prom2 gene mutation were less likely to express genes known to be protective against hereditary ParkinsonΓÇÖs known as PINK-1 and DJ-1/PARK7. People with decreased levels of expression of these genes tend to develop PD at an earlier age than those with normal gene expression.. Together, these findings suggest that SIRT5prom2 may represent a novel indirect risk factor for mitochondria-related diseases such as PD and AlzheimerΓÇÖs diseases.Applications* Provides new strategies for predicting, delaying, and treating neurological diseases* Provides new targets for treating age related diseasesAdvantages* Identify neurological disease pathways largely overlap with molecular aging* Identify subjects carrying a low-expressing version of a longevity gene known as Sirtuin5; SIRT5prom2 are more likely to develop PD at an earlier ageStage of Development* Additional retrospective analysis is continuing

*Principal Investigator

Name: Christin Glorioso

Department: Med-Psychiatry

Name: Etienne Sibille

Department: Med-Psychiatry

Country/Region

USA